Injection of nanoparticle has proven effective in mouse models, researchers say
Researchers at Tel Aviv University have developed a novel nano-vaccine for melanoma, the most aggressive type of skin cancer. Their innovative approach has so far proven effective in preventing the development of melanoma in mouse models and in treating primary tumors and metastases that result from melanoma.
The focus of the research is on a nanoparticle that serves as the basis for the new vaccine. The study was led by Prof. Ronit Satchi-Fainaro, chair of the Department of Physiology and Pharmacology and head of the Laboratory for Cancer Research and Nanomedicine at TAU’s Sackler Faculty of Medicine, and Prof. Helena Florindo of the University of Lisbon while on sabbatical at the Satchi-Fainaro lab at TAU; it was conducted by Dr. Anna Scomparin of Prof. Satchi-Fainaro’s TAU lab and postdoctoral fellow Dr. João Conniot. The results were published on August 5 in Nature Nanotechnology.
Melanoma develops in the skin cells that produce melanin or skin pigment. “The war against cancer in general, and melanoma in particular, has advanced over the years through a variety of treatment modalities, such as chemotherapy, radiation therapy and immunotherapy; but the vaccine approach, which has proven so effective against various viral diseases, has not materialized yet against cancer,” says Prof. Satchi-Fainaro. “In our study, we have shown for the first time that it is possible to produce an effective nano-vaccine against melanoma and to sensitize the immune system to immunotherapies.”
The researchers harnessed tiny particles, about 170 nanometers in size, made of a biodegradable polymer. Within each particle, they “packed” two peptides — short chains of amino acids, which are expressed in melanoma cells. They then injected the nanoparticles (or “nano-vaccines”) into a mouse model bearing melanoma.
“The nanoparticles acted just like known vaccines for viral-borne diseases,” Prof. Satchi-Fainaro explains. “They stimulated the immune system of the mice, and the immune cells learned to identify and attack cells containing the two peptides — that is, the melanoma cells. This meant that, from now on, the immune system of the immunized mice will attack melanoma cells if and when they appear in the body.”
The researchers then examined the effectiveness of the vaccine under three different conditions.
First, the vaccine proved to have prophylactic effects. The vaccine was injected into healthy mice, and an injection of melanoma cells followed. “The result was that the mice did not get sick, meaning that the vaccine prevented the disease,” says Prof. Satchi-Fainaro.
Second, the nanoparticle was used to treat a primary tumor: A combination of the innovative vaccine and immunotherapy treatments was tested on melanoma model mice. The synergistic treatment significantly delayed the progression of the disease and greatly extended the lives of all treated mice.
Finally, the researchers validated their approach on tissues taken from patients with melanoma brain metastases. This suggested that the nano-vaccine can be used to treat brain metastases as well. Mouse models with late-stage melanoma brain metastases had already been established following excision of the primary melanoma lesion, mimicking the clinical setting. Research on image-guided surgery of primary melanoma using smart probes was published last year by Prof. Satchi-Fainaro’s lab.
“Our research opens the door to a completely new approach — the vaccine approach — for effective treatment of melanoma, even in the most advanced stages of the disease,” concludes Prof. Satchi-Fainaro. “We believe that our platform may also be suitable for other types of cancer and that our work is a solid foundation for the development of other cancer nano-vaccines.”
The Latest on: Melanoma
via Google News
The Latest on: Melanoma
- Vaccine May Keep Melanoma in Remission 4 Yearson January 25, 2021 at 10:40 am
Giving melanoma patients a "personalized" vaccine can prompt an anti-tumor immune response that lasts for years, an early study finds.
- Therapeutic Vaccine Is Keeping Melanoma in Remission 4 Years Onon January 25, 2021 at 9:43 am
(HealthDay News) -- Giving melanoma patients a "personalized" vaccine can prompt an anti-tumor immune response that lasts for years, an early study finds. The study involved just eight patients with ...
- FDA Grants Toripalimab Fast Track Designation for Mucosal Melanomaon January 24, 2021 at 4:21 pm
About Toripalimab Toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing in China. More than thirty company-sponsored clinical studies covering more than fifteen ...
- Frances Abbott husband Sam Loch reveals shocking melanoma diagnosis just weeks after baby newson January 24, 2021 at 3:24 pm
Australian former Olympic rower Sam Loch has revealed how a spot on his shin turned out to be a melanoma just weeks after his wife Frances Abbott announced her pregnancy.
- Cancer vaccine helped keep melanoma under control for years in small studyon January 21, 2021 at 10:47 am
A personalized "cancer vaccine" may help keep a deadly form of skin cancer from growing for years, a small new study in humans suggests. Unlike vaccines that prevent infections, such as measles and ...
- Study: Vaccine protects against melanoma recurrence up to 4 yearson January 21, 2021 at 10:15 am
A custom-made vaccine against melanoma still protects against advanced disease four years after cancer patients receive it, according to a study published Thursday by Nature Medicine.
- Vaccine produces long-lasting anti-tumor response in patients with melanomaon January 21, 2021 at 8:06 am
Four years after patients with melanoma were treated with a personalized cancer vaccine, the immune response kindled by the vaccine remains robust and effective in keeping cancer cells under control, ...
- Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Dermatology Conferenceon January 20, 2021 at 9:58 pm
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced poster presentations with ...
- Study reveals significant role of ADAMTS1 protein in uveal melanomaon January 17, 2021 at 6:22 pm
Scientists from the University of Granada and GENYO (Pfizer-University of Granada-Andalusian Government Centre for Genomics and Oncological Research), in a study led by Juan Carlos ...
- Global Non-Melanoma Skin Cancer Market Size 2021, Share, Growth, Industry Analysis and Future Demand, Top Key Players and Forecast 2026on January 14, 2021 at 4:45 pm
Melanoma Skin Cancer Market provides detailed analysis of Market Overview, Drivers, Prospects, Potential Application. Also Non-Melanoma Skin Cancer Industry research report includes the future impact ...
via Bing News